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Objectives We investigated the 6-month clinical outcomes after implantation of second-generation 3.0-mm bioresorbable
everolimus-eluting vascular scaffolds (BVS) in small coronary vessels (2.5 mm).
Background BVS are a novel approach to treating coronary lesions and are untested in small vessels.
Methods The ABSORB Cohort B Trial is a multicenter, single-arm, prospective, open-label trial assessing the performance
of the second-generation BVS, in which 101 patients were enrolled. The pre-procedural reference vessel diame-
ter (RVD) was assessed by quantitative coronary angiography during post hoc analysis. The vessel size was over-
estimated, by visual assessment, in 41 patients before implantation of 3.0-mm BVS in vessels with a pre-
procedural RVD 2.5 mm. The study population was divided into 2 groups, group I (n  41) with RVD 2.5 mm
and group II (n  60) with RVD 2.5 mm. The composite endpoint of ischemia-driven major adverse cardiac
events, defined as ischemia-driven target lesion revascularization, myocardial infarction, or cardiac death, was
assessed. Of the 45 patients scheduled for 6-month coronary angiography, 42 patients had the procedure per-
formed, with intravascular ultrasound undertaken in 40 of these patients.
Results At 6 months, no significant differences in ischemia-driven major adverse cardiac events (3 of 41 [7.3%] cases
vs. 2 of 60 [3.3%] cases; p  0.3933) were observed in the small- and large-vessel groups, respectively. No car-
diac deaths or episodes of in-scaffold thromboses were seen. Angiographic and intravascular ultrasound
follow-up demonstrated no differences in late lumen loss (0.16  0.18 mm vs. 0.21  0.17 mm; p  0.3525)
or percentage lumen area stenosis (17.6  6.0% vs. 19.8  8.5%; p  0.3643).
Conclusions The second-generation 3.0-mm BVS appears to be safe in small vessels, with similar clinical and angiographic
outcomes compared with those of large vessels. (J Am Coll Cardiol 2011;58:258–64) © 2011 by the American
College of Cardiology Foundation
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July 12, 2011:258–64 Second-Generation BVS in Small VesselsFully bioresorbable drug-eluting vascular scaffolds (BVS, Ab-
bott Vascular, Santa Clara, California) are a novel approach to
treating coronary lesions in that they provide transient vessel
support and drug delivery to the vessel wall. The first-
generation BVS demonstrated slightly higher acute and late
recoil when compared with conventional metallic stents. (1,2)
To further enhance support of the vessel wall, the strut design
and manufacturing processes of the polymer were modified,
leading to the BVS revision 1.1; this device was subsequently
investigated in the ABSORB Cohort B trial. Because of the
single size availability of the BVS (3.0 mm in diameter), the
target lesions were required to be located in vessels with a
visually estimated vessel diameter of 3.0 mm. However,
during the clinical use of BVS, more than one-third of the
scaffolds were found to have been deployed in vessels with a
pre-procedural reference vessel diameter (RVD) 2.5 mm.
This protocol deviation has provided the opportunity to
assess the performance of the 3.0-mm BVS device in these
vessels.
The purpose of this substudy was therefore to investi-
gate the clinical and angiographic outcomes after implan-
tation of the new generation of BVS in small coronary
vessels (RVD 2.5 mm).
Methods
Study design and population. The study design and de-
vice have previously been described (3). In brief, 101
patients were enrolled in the ABSORB Cohort B study and
implanted with 3-mm BVS. Assessment of vessel size
before BVS implantation was made by visual estimation of
the operator. In the present post hoc analysis, the study
population was divided into 2 groups based on the RVD
before intervention. Group I included 41 patients (41
lesions) with an RVD 2.5 mm, and group II included 60
patients (61 lesions) with an RVD 2.5 mm. Of the 45
patients initially scheduled for 6- and 24-month coronary
angiography, 42 patients underwent the procedure at the
6-month follow-up, with intravascular ultrasound (IVUS)
analyses performed in 40 cases.
Quantitative coronary angiography and IVUS analysis.
In all patients, analyses were performed with quantitative
coronary angiography (QCA) using a coronary angiography
analysis system (Pie Medical Imaging, Maastricht, the
Netherlands). The RVD was obtained by the interpolated
method (4). Post-procedural and follow-up scaffold seg-
ments were analyzed with phased-array IVUS catheters
(EagleEye, Volcano Corporation, Rancho Cordova, Cali-
fornia), with an automated pullback of 0.5 mm/s. Images
were analyzed offline with semiautomatic contour detection
provided by dedicated software, as previously reported (3).
has received honoraria from Abbott Vascular and Boston Scientific. Dr. Serruys is a member
of the Abbott Vascular BVS Scientific Advisory Group. All other authors have reported that
they have no relationships to disclose.Manuscript received November 2, 2010; revised manuscript received February 7,
2011, accepted February 22, 2011.Statistical analysis. Categorical
variables are presented as counts
and percentages. Continuous vari-
ables are presented as mean SD.
The p values were calculated with
the Fisher exact test for binary
variables and Wilcoxon rank-sum
test for continuous variables. All
p values were calculated for de-
scriptive purposes and did not
form part of formal hypothesis
tests. Statistical analyses were
performed using SAS (version
9.1.3, SAS Institute, Inc., Cary,
North Carolina).
Results
Baseline characteristics and
procedural outcomes. In the
ABSORB Cohort B Trial, 101 patients were enrolled and
102 lesions treated with implantation of BVS. Forty-one
lesions had an RVD 2.5 mm, and 61 lesions had an RVD
2.5 mm (Fig. 1). In the small-vessel group, 34 lesions (83%)
were located in the mid or distal part of main coronary arteries
or in secondary branches. No significant differences in baseline
demographic characteristics were seen in both groups (Table 1).
Comparable pre-procedural percentage diameter stenoses
(57.0  9.3% vs. 60.3  10.3%; p  0.1000) and post-
procedural acute gains (1.21  0.30 mm vs. 1.25  0.33 mm;
p  0.4946) were observed (Table 2).
Clinical outcomes. No statistically significant differences
were observed in the incidences of both in-hospital (small-
vessel group 2 of 41 cases [4.9%]; large-vessel group 0 of 60
cases [0%]; p  0.1624) and 6-month (small-vessel group 3
of 41 cases [7.3%]; large-vessel group 2 of 60 cases [3.3%];
p  0.3933) major adverse cardiac events (MACE) in both
groups (Table 3). At 6 months, the incidences of ischemia-
driven target lesion revascularizations (ID-TLR) (1 of 41
patients [2.4%] vs. 1 of 60 patients [1.7%]; p  1.0000),
target vessel revascularizations (2.4% vs. 1.7%; p  1.0000),
and myocardial infarctions (2 of 41 patients [4.9%] vs. 1 of
60 patients [1.7%]; p 0.5645) were similar in both groups,
with no cardiac deaths observed. At 6 months, no episodes
of scaffold thromboses, as defined by the Academic Re-
search Consortium (5), were reported. One episode of a
non-ID-TLR event was seen in the large-vessel group.
6-month angiographic and IVUS results. QCA analyses
at 6 months were available for 42 patients (small-vessel
group n  19; large-vessel group n  23). No statistical
differences in scaffold percentage diameter stenoses (18.1 
7.2% vs. 20.2  8.0%; p  0.3736) and in scaffold late loss
(0.16  0.18 mm vs. 0.21  0.17 mm; p  0.3525) were
observed between both groups. No cases of binary restenosis
Abbreviations
and Acronyms
BVS  bioresorbable drug-
eluting vascular scaffolds
CK  creatine kinase
DES  drug-eluting stent(s)
ID-TLR  ischemia-driven
target lesion
revascularization
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac event(s)
OCT  optical coherence
tomography
QCA  quantitative
coronary angiography
RVD  reference vessel
diameterwithin the scaffold were evident in either group (Table 4).
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Second-Generation BVS in Small Vessels July 12, 2011:258–64Figure 1 Distribution of Pre-Implantation RVD in ABSORB Cohort B Trial Population
More than one-third of the treated lesions (40.2%) in the ABSORB Cohort B trial had a pre-implantation reference vessel diameter (RVD) 2.5 mm.Baseline Characteristics of ITT PopulationTable 1 Baseline Characteristics of ITT Population
Small Vessels
(<2.5 mm; n  41)
Large Vessels
(>2.5 mm; n  60) p Value
Age, yrs 62.4 9.4 (n  41) 62.2 8.7 (n  60) 0.9193
Male 26/41 (63.4) 47/60 (78.3) 0.1169
Current tobacco use 9/41 (22.0) 8/59 (13.6) 0.2917
Diabetes 9/41 (22.0) 8/60 (13.3) 0.2875
Hypertension requiring medication 24/41 (58.5) 38/59 (64.4) 0.6757
Hypercholesterolemia requiring medication 35/41 (85.4) 44/60 (73.3) 0.2196
Family history of coronary artery disease 23/38 (60.5) 30/59 (50.8) 0.4065
Prior PTCA 6/41 (14.6) 15/60 (25.0) 0.3180
Prior CABG 1/41 (2.4) 2/60 (3.3) 1.0000
Prior MI 7/40 (17.5) 18/60 (30.0) 0.2382
Target vessel
RCA 13/41 (31.7) 21/61 (34.4) 0.8326
LAD 19/41 (46.3) 25/61 (41.0) 0.6845
LCX 8/41 (19.5) 15/61 (24.6) 0.6332
American College of Cardiology/
American Heart Association lesion class
A 0/40 (0.0) 1/60 (1.7) 1.0000
B1 21/40 (52.5) 34/60 (56.7) 0.6878
B2 18/40 (45.0) 22/60 (36.7) 0.4143
C 1/40 (2.5) 3/60 (5.0) 0.6479
Values are mean  SD or n/N (%).
CABG  coronary artery bypass graft; ITT  intention to treat; LAD  left anterior descending; LCX  left circumflex; MI myocardial infarction;
PTCA  percutaneous transluminal coronary angioplasty; RCA  right coronary artery.
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significant differences in lumen area stenosis (17.6  6.0%
vs. 19.8 8.5%; p 0.3643) or neointimal hyperplasia area
(0.06  0.12 mm2 vs. 0.09  0.12 mm2; p  0.4084)
between the 2 groups (Table 5, Fig. 2).
However, the comparison of IVUS results is limited by
the small number of available data; a post hoc power analysis
showed that with this sample size, a difference in neointimal
hyperplasia area of 0.11 mm2 could be detected with 80%
power.
Case descriptions of MACE and non–ID-TLR events.
In the small-vessel group, 3 MACE were reported. In the
first patient (RVD 2.05 mm), the 6-month scheduled
angiography disclosed a proximal-edge stenosis in the mid
right coronary artery that was subsequently treated. Of note
is that during the index procedure, the operator deeply
inserted the Amplatz guide catheter into the mid right
coronary artery; the possibility of endothelial denudation
therefore cannot be excluded as a potential cause of the
restenosis. In the second patient (RVD 2.15 mm), pre-
dilation of the lesion provoked a dissection that became
Baseline QCA Characteristics Before and After the Procedure in ITTable 2 Baseline QCA Characteristics Before and After the Pro
Small Vessels
(<2.5 mm; n  41)
Before procedure
RVD, mm 2.27 0.15 (41)
MLD, mm 0.97 0.20 (39)
Percent diameter stenosis, % 57.0 9.3 (39)
After procedure
In-scaffold MLD, mm 2.17 0.22 (41)
In-scaffold percent diameter stenosis, % 13.8 4.0 (41)
In-scaffold acute gain, mm 1.21 0.30 (39)
Values are mean  SD (n).
CI  confidence interval; MLD  minimal lumen diameter; QCA  quantitative coronary angiog
Adverse Events at 6-Month Follow-UpTable 3 Adverse Events at 6-Month Follow-Up
Small Vessels
(<2.5 mm; n  41)
Large Vessels
(>2.5 mm; n  60) p Value
ID-MACE* 3/41 (7.3) 2/60 (3.3) 0.3933
Cardiac death 0/41 (0.0) 0/60 (0.0) NA
MI 2/41 (4.9) 1/60 (1.7) 0.5645
QMI 0/41 (0.0) 0/60 (0.0) NA
NQMI 2/41 (4.9) 1/60 (1.7) 0.5645
ID-TLR 1/41 (2.4) 1/60 (1.7) 1.0000
CABG 0/41 (0.0) 0/60 (0.0) NA
PCI 1/41 (2.4) 1/60 (1.7) 1.0000
Non–ID-TLR 0/41 (0.0) 0/60 (0.0) NA
CABG 0/41 (0.0) 0/60 (0.0) NA
PCI 0/41 (0.0) 1/60 (1.7) 1.0000
Values are n (%). *Cardiac death, MI, and ID-TLR.
ID-MACE ischemia-drive major adverse cardiac events; ID-TLR ischemia-driven target lesion
revascularization; NA  not applicable; NQMI  non–Q-wave myocardial infarction; PCI 
percutaneous coronary intervention; QMI  Q-wave myocardial infarction; other abbreviations
as in Table 1.occlusive after incomplete lesion coverage with the BVS.
Subsequent bailout stenting was performed. The peak value
of troponin was 0.8 ng/ml (upper limit of normal [ULN]
0.03 ng/ml), creatine kinase (CK) 521 U/l (ULN 180
U/l), and CK-MB 48 U/l (ULN 5 U/l). This case was
adjudicated as peri-procedural non–Q-wave myocardial in-
farction. In the third patient (RVD 2.18 mm), a nonocclu-
sive dissection occurred after lesion pre-dilation; however,
the dissection was fully covered with BVS. The electrocar-
diogram remained unremarkable. Subsequent troponin,
CK, and CK-MB levels, however, peaked at 0.81 ng/ml
(ULN 0.03 ng/ml), 667 U/l (ULN 150 U/l), and 97.2
ng/ml (ULN 4 ng/ml), respectively.
In the large-vessel group, 2 MACE were reported. In the
first patient (RVD 2.51 mm), BVS was implanted in the left
anterior descending artery with a myocardial bridge. Three
months later, the patient presented with recurrent angina.
Repeat coronary angiography demonstrated a diameter ste-
nosis of 40% and 85% in diastole and systole, respectively,
resulting in the implantation of a metallic everolimus-
eluting stent. In the second patient (RVD 2.74 mm), an
iatrogenic non–Q-wave myocardial infarction (CK 600 U/l,
CK-MB 72 U/l, 2 ULN) was caused by thrombus
formation following an IVUS examination, during a failed
attempt at imaging the vessel with optical coherence tomog-
raphy (OCT).
In a separate patient, 3.0-mm BVS was post-dilated with
a larger 3.5-mm semicompliant balloon to 16 atmospheres
(expected diameter 3.96 mm). Post-procedural OCT re-
vealed several scaffold pattern irregularities but with a 20%
diameter stenosis; consequently, there was no further inter-
vention. Thirty-three days later, the patient was readmitted
because of recurrent nocturnal chest pain. Coronary angiog-
raphy demonstrated a nonsignificant diameter stenosis of
23%. OCT however, revealed multiple scaffold pattern
irregularities in the proximal half of the BVS with several
struts appearing in the middle of the lumen. A 3.5-mm
drug-eluting stent (DES) was deployed in the proximal
BVS with a satisfactory result. This event was adjudicated as
ulationre in ITT Population
Large Vessels
(>2.5 mm; n  60) Difference (95% CI) p Value
2.83 0.29 (61) –0.56 (–0.65 to –0.48) 0.0001
1.12 0.30 (59) –0.15 (–0.25 to –0.05) 0.0044
60.3 10.3 (59) –3.3 (–7.3 to 0.7) 0.1000
2.37 0.23 (61) –0.21 (–0.30 to –0.12) 0.0001
16.2 6.7 (61) –2.4 (–4.5 to –0.3) 0.0280
1.25 0.33 (59) –0.04 (–0.17 to 0.08) 0.4946
RVD  reference vessel diameter; other abbreviation as in Table 1.T Popcedu
raphy;being a non–ID-TLR by the Clinical Events Committee.
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The present substudy of ABSORB Cohort B is the first to
report the use of a completely bioresorbable everolimus-
eluting scaffold in the setting of small-vessel disease. The
major findings of this substudy were: 1) patients who
underwent BVS implantation in small vessels had 6-month
clinical outcomes similar to those of patients who under-
went the procedure in large vessels; and 2) implantation of
3-mm BVS in small vessels was associated with equivalent
late luminal loss, percentage diameter stenosis, and binary
restenosis rates, compared with those of large vessels.
Small-vessel coronary artery disease is a recognized chal-
lenging subset within the field of coronary artery interven-
tion in that balloon angioplasty and bare metal stents have
previously demonstrated unacceptable rates of restenosis
and MACE (6,7). The use of DES in this setting has,
however, led to more acceptable long-term results, although
important differences in types of DES appear to exist (8,9).
QCA Analysis at Baseline and 6-Month Follow-UpTable 4 QCA Analysis at Baseline and 6-Month Follow-Up
Small Vessels
(<2.5 mm; n  20)
Baseline QCA analysis
Before procedure
RVD, mm 2.24 0.17 (20)
MLD to mm 0.93 0.22 (19)
Percent diameter stenosis, % 58.0 11.1 (19)
After procedure
In-scaffold acute gain, mm 1.23 0.37 (19)
6-month QCA analysis
In-scaffold late loss, mm 0.16 0.18 (19)
In-scaffold percent diameter stenosis, % 18.1 7.2 (19)
In-scaffold binary restenosis 0.0% (0/19)
Values are mean  SD (n).
Abbreviations as in Tables 2 and 3.
IVUS Analysis at Baseline and 6-Month Follow-UpTable 5 IVUS Analysis at Baseline and 6-Month Follow-Up
Small Vessels
(<2.5 mm; n  20)
Baseline IVUS analysis
Average vessel area, mm2 11.85 3.36 (18)
Average lumen area, mm2 5.84 0.99 (18)
Average scaffold area, mm2 5.86 0.98 (18)
Average plaque area, mm2 6.01 2.66 (18)
6-month IVUS analysis
Average vessel area, mm2 12.46 3.26 (19)
Average lumen area, mm2 5.79 0.93 (19)
Average scaffold area, mm2 5.84 0.91 (19)
Average plaque area, mm2 6.67 2.53 (19)
Minimal lumen area, mm2 4.78 0.90 (19)
Lumen area stenosis, % 17.6 6.0 (19)
Area obstruction, % 1.1 2.2 (19)
Neointimal hyperplasia area, mm2 0.06 0.12 (19)Values are mean  SD (n).
IVUS  intravascular ultrasound; other abbreviation as in Table 2.In the present study, despite the implantation of larger
(3.0-mm) BVS in small vessels (2.5 mm), no significant
differences in clinical outcomes were observed in both
groups at 6 months. In the small-vessel group, all 3 cases
may possibly have been explained by procedural-related
complications and not due to device failure itself. However,
because of the small sample size and low incidence rate in
this study, caution should be taken in making firm conclu-
sions with regards to safety and efficacy.
A high degree of vessel stretch and injury, smaller
post-procedural lumen area, and a high metal density have
all previously been proposed as contributing factors to
explain the poorer outcomes associated with small vessels
(10). Current consensus, however, is that the so-called
“bigger is better” paradigm (11) is likely to be the most
plausible mechanism to explain the poorer outcomes asso-
ciated with small-vessel disease. Effectively, a smaller vessel
size would be less able to accommodate the same absolute
volume of neointimal hyperplasia as a larger vessel, with the
Large Vessels
2.5 mm; n  25) Difference (95% CI) p Value
2.96 0.33 (25) 0.72 (0.88 to0.57) 0.0001
1.15 0.35 (25) 0.22 (0.40 to0.04) 0.0154
60.8 11.9 (25) 2.8 (9.9 to 4.2) 0.4216
1.29 0.35 (25) 0.05 (0.28 to 0.17) 0.6269
0.21 0.17 (23) 0.05 (0.16 to 0.06) 0.3525
20.2 8.0 (23) 2.1 (6.8 to 2.6) 0.3736
0.0% (0/23) 0.0% (assumption not met) NA
Large Vessels
2.5 mm; n  25) Difference (95% CI) p Value
6.40 2.87 (22) 4.55 (6.59 to2.52) 0.0001
7.22 0.96 (22) 1.38 (2.01 to0.75) 0.0001
7.16 0.92 (22) 1.30 (1.91 to0.68) 0.0001
9.18 2.29 (22) 3.17 (4.79 to1.55) 0.0003
6.28 2.75 (21) 3.82 (5.76 to1.88) 0.0003
6.87 0.96 (21) 1.08 (1.68 to0.47) 0.0009
6.94 0.94 (21) 1.10 (1.69 to0.51) 0.0006
9.41 2.15 (21) 2.74 (4.26 to1.23) 0.0008
5.49 0.87 (21) 0.72 (1.28 to0.15) 0.0143
19.8 8.5 (21) 2.1 (6.8 to 2.6) 0.3643
1.4 1.9 (21) 0.3 (1.6 to 1.0) 0.6363
0.09 0.12 (21) 0.03 (0.11 to 0.05) 0.4084(>(>
1
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July 12, 2011:258–64 Second-Generation BVS in Small Vesselsresultant increase in the rate of binary restenosis. The other
potential concern is the thickness of the BVS struts (150
m) because previous studies have suggested a link between
thicker struts and an increased risk of restenosis (12); these
concerns, however, did not appear to be evident in this
present study.
Vessels with RVD 2.5 mm were treated with 3.0-mm
Figure 2 Small Vessel Treated With Implantation of BVS
Angiographic, optical coherence tomography (OCT), and intravascular ultra-
sound (IVUS) images before procedure, after procedure, and at 6-month
follow-up are shown. The images show an example of a small vessel treated
with a bioresorbable drug-eluting vascular scaffold (BVS) (pre-RVD 2.24 mm).
(A) A visual comparison between the vessel-treated segment and a 6-Fr cathe-
ter (1.98 mm) is highlighted. Pre-procedural angiography and quantitative coro-
nary angiography (QCA) analysis revealed a minimal lumen diameter (MLD) of
0.65 mm. Post-procedural angiography (left panel) and QCA analysis demon-
strated an MLD of 2.01 mm. At the 6-month follow-up (right panel), the MLD
was 2.23 mm. For illustrative purposes, the OCT (B) and IVUS (C) images are
presented. These are corresponding frames taken from the MLD. A small side
branch (*) located at the post-procedural MLD was used as a landmark for
accurate matching of the images among different imaging modalities (angiogra-
phy, OCT, and IVUS) and between the 2 time points. Abbreviations as in Figure 1.VS pre-mounted on a 3.0-mm diameter balloon. Thisactor may have played a role in the similar angiographic and
linical outcomes observed between the 2 groups. Further
tudy of this device is currently being undertaken in the
ulticenter ABSORB Extend Single-Arm Study, in which
he introduction of a 2.5-mm BVS device is planned. This
.5-mm BVS device is actually the same scaffold as the 3.0
m but crimped onto a smaller 2.5-mm balloon and is
ntended for the treatment of vessels 2.0 and 3.0 mm.
This smaller device may aid in further understanding
whether the impact of a larger (3.0-mm) deployment
balloon size played any significant role in the excellent
outcomes seen with the device in small vessels.
It would therefore appear that the concerns of BVS
implantation in small vessels may not be justified, whereas
the risk of excessive post-dilation of the BVS appears to be
of more concern. Appropriate sizing of the vessel with QCA
analysis and respect for the maximal diameter limits of the
BVS are therefore currently required.
Study limitations. The present study was a post hoc
analysis, and the number of patients was limited. Therefore,
p values presented are exploratory and should be interpreted
with caution. Second, coronary angiography is limited to the
detection of the lumen contour, without the actual vessel
size being taken into account. IVUS allows assessment of
the vessel size; however, IVUS was not performed before
BVS implantation in the present study.
Conclusions
The 3.0-mm BVS appears to be safe and effective in small
vessels, with similar clinical and angiographic outcomes
observed when compared with those of large vessels.
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